Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as a tablet for oral use. It is used to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimotop is a calcium channel blocker used in the management of cerebral vasospasm after subarachnoid hemorrhage.

Cerebral vasospasm after subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits.

Nimotop may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Flushing or warmth sensation. - Nausea or vomiting. - Low blood pressure (hypotension). - Peripheral edema.

Serious or Rare Side Effects: - Severe hypotension or shock. - Bradycardia or heart block. - Allergic reactions including rash, pruritus, or anaphylaxis. - Hepatic enzyme elevation or liver injury. - Hematologic abnormalities such as neutropenia. - Myocardial infarction or cardiac ischemia.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: watch for symptomatic hypotension. Assess hepatic function: use cautiously in patients with liver impairment. Avoid abrupt discontinuation: taper if long‑term therapy is required. Review concomitant antihypertensives: adjust doses to prevent additive effects. Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. Store at below 25°C: keep in the original pack, protect from moisture.

Nimotop can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase plasma levels. - Concurrent use with other calcium‑channel blockers: risk of excessive vasodilation. - Nitrates or other potent vasodilators: additive hypotensive effect. - Grapefruit juice: can raise nimodipine concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: may potentiate blood‑pressure lowering. - Antacids containing aluminum or magnesium: could affect absorption. - Beta‑blockers: monitor for bradycardia. - Anticoagulants: observe for bleeding if hypotension occurs.